Getting emails back. Dear DRR, Thank you for w

Getting emails back.

Dear DRR,

Thank you for writing the Division of Drug Information in the FDA's Center for Drug Evaluation and Research.

FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.

Please note that due to confidentiality laws, the FDA cannot divulge information related to applications that may or may not have been submitted to the Agency. All information on an unapproved drug product is confidential and belongs to the sponsor.

You may also be interested in visiting our COVID-19 Drugs page.

Best regards,

SL
Pharmacist
Division of Drug Information
Center for Drug Evaluation and Research
Tel: 855-543-DRUG (855-543-3784)
druginfo@fda.hhs.gov

Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com